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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Neutropenia is a risk factor for nosocomial infections (NI) in very-low-
birth-weight (VLBW) infants. Although recombinant human granulocyte colony stimulating
factor (rhG-CSF) increases the neutrophil counts in neutropenic VLBW infants, its long-term
efficacy for early neutropenia (EN) remains unknown.
Methods: In this case-controlled study, charts of VLBW recipients of rhG-CSF for EN (total
neutrophil count <1.5  109/L during first 7 days) were reviewed and compared to gestational
age, total neutrophil count, and birth weight matched infants unexposed to rhG-CSF.
Results: Twenty-seven infants were identified in each group. Mortality and morbidity did not
differ between the two groups. Rate of NI (16/27 vs. 4/27, p Z 0.002, odds ratio Z 8.36) as
well as the total number of episodes of NI (22 vs. 4, p Z 0.007) were higher in rhG-CSF (þ)
group than in the rhG-CSF (e) group.
Conclusion: Our experience does not show benefit in empirical use of rhG-CSF in preventing NI
in VLBW infants with EN.
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Neutrophils play an important role in host defense against
infections. Neutropenia is common in premature infants and
neutrophil function is impaired1 in this group. Neutropenia
usually develops in the first week of life, affects 5e68% of
premature infants, and is normally transient.2e4 Manroe et al& Formosan Medical Association. All rights reserved.
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infection in newborn infants.5 Subsequent studies supported
the contention that early neutropenia (EN) in premature
infants may increase the incidence of nosocomial infection
(NI) especially when it is associated with maternal hyper-
tension.6,7 It has been proposed that increasing the neutro-
phil count in neutropenic premature infants by either
recombinant human granulocyte-colony-stimulating
factor (rhG-CSF),8e10 or granulocyte-macrophage-colony-
stimulating factor (rhGM-CSF)11 may prevent or decrease
NI. There is one randomized controlled trial published in
neonatal neutropenia, developed within 21 days (mean
>4 days) of life, to study prophylactic rhG-CSF use in
decreasing NI in premature infants which demonstrates
efficacy for only 2 weeks.12 The Cochrane Review finds no
sufficient evidence to support the introduction of either G-
CSF or GM-CSF into neonatal practice, either as treatment of
established systemic infection to reduce mortality, or as
prophylaxis to prevent systemic infection in high risk
neonates.13 Nonetheless, some neonatologists empirically
administer rhG-CSF to premature infants with EN on the
assumption that it reduces the risk of NI. This practice
prompted us to review our own experience. We previously
reported that EN, developed in the 1st week of life, is not
associated with increased incidence of NI in very-low-birth-
weight (VLBW) infants.14 We now examine the efficacy of
empirical use of rhG-CSF for EN in this group of infants.Methods
Records of VLBW infants admitted to the neonatal intensive
care unit of University of Florida Health Science Center at
Jacksonville, between January 2002 and July 2004, were
reviewed with the approval of the Institutional Review
Board (UF-IRB3). There were totally 338 VLBW infants with
gestational age <34 weeks that were admitted during this
period. EN was defined as a total neutrophil count (TNC)
<1.5  109/L within the 1st week of life. Infants who
developed neutropenia within 24 hours of a positive
culture, or those who received rhG-CSF within 24 hours of
a positive culture, were excluded. Empirical rhG-CSF
(5e10 mg/kg/day for 3e5 days) for EN, once daily via
intravenous lines, was prescribed at the discretion of the
attending neonatologist(s). Our group determined as the
unit policy to give rhG-CSF via the intravenous route after
discussion with our pharmacists.
Total white cell counts were obtained using an auto-
matic cell counter after correction for nucleated red blood
cells. TNC were obtained by multiplying total white cell
counts by the sum of percentages of segment, band, and
metamyelocyte. NI was defined as a positive culture of
a body fluid after 3 days of life. Two positive cultures ob-
tained from two different sites on the same day were
required to categorize coagulase-negative Staphylococcus
as a true NI. The time of positive culture was defined as the
time when it was drawn. Microbiology reports were ob-
tained from the hospital mainframe computer system and
cross-referenced with both medical record number and
date of birth of the patient. The computerized database of
hospital pharmacy was used to identify the dates and times
of administration of all prescriptions of rhG-CSF.VLBW infants who received empirical rhG-CSF for EN and
fulfilled our predetermined criteria were included in rhG-
CSF (þ) group. During the same period, VLBW infants with
EN but unexposed to rhG-CSF and matched for gestational
age (1 week), birth weight (150 g), and the lowest TNC
in the 1st week of life (250  106/L) comprised the rhG-
CSF (e) group.
Gestational age (GA) was determined either by the last
menstrual period or prenatal ultrasound before 20 weeks’
gestation. Birth weight below the 10th percentile of the
corresponding gestational age was defined as small for
dates. Maternal hypertension included pre-eclampsia/
eclampsia, chronic hypertension, and HELLP syndrome.
Central line was placed by a team of health professionals,
used only for parenteral nutrition, and was considered as
positive when NI occurred in the presence of central line(s).
Oxygen requirement at 28 days was defined as broncho-
pulmonary dysplasia, whereas oxygen usage after post-
conceptional age of 36 weeks was defined as chronic lung
disease (CLD). Necrotizing enterocolitis (NEC) was defined
using modified Bell’s staging criteria15 and included infants
with Stage II or higher NEC. An outcome of patent ductus
arteriosus was assigned if an infant was treated either with
indomethacin or ibuprofen or by surgical ligation. Papile’s
classification16 was used to grade intraventricular hemor-
rhage. Age of NI was determined by the date of positive
culture(s).
Statistical analysis
Data were analyzed after de-identification. All continuous
variables were analyzed by nonparametric test (paired and
nonpaired) and expressed as median (interquartile range,
IQR). Odds ratios (OR) with 95% confidence intervals (CI)
were obtained for Fisher’s exact test. In order to avoid
inappropriate matching, data of all infants with EN were
entered into multivariate logistic regression using NI as the
dependent variable with GA, birth weight, sex, premature
rupture of membranes, maternal hypertension, central line
usage, total days on parenteral nutrition, small for date
status, lowest TNC within the first 7 days, and prophylactic
use of rhG-CSF for EN as independent variables. Log rank
test was used to compare the probability of NI between
rhG-CSF (þ) and rhG-CSF (e) groups and hazard ratio (with
95% CI) was obtained. A p-value <0.05 for any independent
variable was interpreted as significant. MedCalc version
12.2 was used for statistical analyses.
Results
Of 338 VLBW infants, 332 had hemogram data within the 1st
week of life. Among these 332 infants, 113 (34.0%) devel-
oped EN and 31 received rhG-CSF. Eleven infants were
excluded due to early infection (8 infants) or dying within
72 hours after birth (3 infants; Fig. 1). Of the remaining 102
VLBW infants with EN not associated with infection, 27
(26.5%) received empirical rhG-CSF within 5 days after birth
(medianZ 1 days, IQR: 0e2 days). These infants comprised
the rhG-CSF (þ) group. We selected 27 infants in the rhG-
CSF (e) group who matched infants in the rhG-CSF (þ)
group. These two groups were compatible with the
Figure 1 The flowchart of patient distribution. CBC Z complete blood count; G-CSF Z granulocyte colony stimulating factor;
NI Z nosocomial infection; NP Z neutropenia.
176 R.-J. Teng et al.exception that the percentage of small for date infants was
lower in the rhG-CSF (þ) group (4/27 vs. 12/27, pZ 0.035;
Table 1). The incidence of bronchopulmonary dysplasia,
CLD, NEC, and intraventricular hemorrhage did not differ
between the two groups. We did not observe any platelet
count <10.0  109/L after rhG-CSF or neutrophilia
(TNC > 14.5  109/L). No other episode of noninfection-
related neutropenia was identified after rhG-CSF treat-
ment. Nursing records did not identify any suggestive
adverse effect during rhG-CSF treatment.
Infants in the rhG-CSF (þ) group experienced a higher
incidence of NI (16/27 vs. 4/27; OR Z 8.36, 95% CI:
2.26e31.00, pZ 0.002) than the infants in the rhG-CSF (e)
group. There were 22 total episodes of NI for infants in the
rhG-CSF (þ) group compared to only four total episodes in
the rhG-CSF (e) group (p Z 0.007, t Z 0.466). In the rhG-
CSF (þ) group, four infants experienced multiple episodes
of NI. Logrank test showed a higher hazard ratio (5.50; 95%
CI: 2.1e14.4, p Z 0.0005, Fig. 2) for the rhG-CSF (þ)
infants to have NI. Multivariate logistic regression analysis
showed that only prophylactic use of rhG-CSF for EN is
associated with the development of NI (r2 Z 0.34). In the
rhG-CSF (þ) group, one infant experienced an episode of NI
with polymicrobial pathogens and another infant experi-
enced one episode of NI with positive cultures from both
blood and catheterized urine with the same pathogen. The
majority of the pathogens were Gram-positive cocci (12/
26) followed by Gram-negative rods (11/26), and fungal
pathogens accounting for the remaining infections. The
median age of NI was 16.5 days for infants in the rhG-CSF
(þ) group, which was not different from infants in the
rhG-CSF (e) group (median of 17.5 days, p Z 0.887)
(Fig. 3).
The TNC (9e1088  106/L; median: 480  106/L; IQR:
188e861  106/L) among all 27 infants before administra-
tion of rhG-CSF increased (25e8462  106/L; median:
1596  106/L; IQR: 821e2034  106/L) after the first dose of
rhG-CSF (p < 0.0001). Among all infants in rhG-CSF (þ)
group, there was no difference (p Z 0.39) in TNC prior to
rhG-CSF administration between those who developed NI
(32e1088  106/L) and those who did not (9e1080  106/L ;
p Z 0.39). There was also no significant difference in the
change in TNC following the first dose of rhG-CSF between
the NI and no-NI sub-groups (range: 288e8466  106/L vs.
25e1836  106/L, p Z 0.25), which suggests that thedifference in rate of NI was not due to a lack of response to
rhG-CSF.
A full analysis of all 102 infants with EN showed empir-
ical rhG-CSF use (OR Z 8.64; 95% CI: 2.78e26.81;
p < 0.001), total days on parenteral nutrition (OR Z 1.05;
95% CI: 1.01e1.10; pZ 0.026), and GA (ORZ 0.77; 95% CI:
0.59e1.00; p Z 0.053) were significantly associated with
NI (area under receiver operating characteristic
curve Z 0.865 with 95% CI: 0.783e0.925; r2 Z 0.462,
p < 0.001). The findings suggested that empirical use of
rhG-CSF for EN does not prevent NI in premature infants.Discussion
Neutropenia can be due to decreased production or
increased consumption of neutrophils, excessive neutrophil
margination, or some combination of these three mecha-
nisms.17 The most commonly encountered causes of neu-
tropenia in VLBW infants are related to maternal
hypertension and sepsis.17 In this investigation, 34% of
enrolled VLBW infants experienced EN which is similar to
previous reports.2e4 Others6,7 reported EN in about 25e50%
of the infants born to mothers with hypertension. This
variety of neutropenia is often associated with a lower
blood concentration of G-CSF18 and is believed to be due to
the release of an inhibitory factor from the placenta that
reduces neutrophil production. Previous studies have sug-
gested that neutropenia associated with maternal hyper-
tension places these premature infants at a higher risk of
NI6,7 but our own experience refuted such association.14
NI is an important contributor to mortality and morbidity
in premature infants. It is associated with a longer duration
of hospitalization and increased hospital costs.19e23 About
20% of all VLBW infants develop at least one episode of NI
during their hospitalization.24e26 One report found a three-
fold higher mortality rate among infants who experienced
at least one episode of NI compared to infants who did
not.26 Prolonged parenteral nutrition, invasive line place-
ment, prolonged mechanical ventilation, and neutropenia
have all been suggested to increase the risk for NI. During
the last 2 decades, prophylactic interventions to reduce NI
have included use of intravenous immunoglobulin,21,24
prophylactic antibiotics,27 and other biological
compounds,28 but none of these treatments has been
Table 1 Demographic data, morbidity, mortality, and
infectious pathogen(s) of very-low-birth-weight infants with
early neutropenia according to the empirical rhG-CSF
treatment.
rhG-CSF(þ) rhG-CSF(e) p
Gestational age (wk) 23.3e34.3 23.1e33.6 0.603
Birth weight (g) 325e1168 520e1281 0.098
Central line (d) 4e44 6e47 0.654
Central line 26/27 27/27 1.000
Lowest TNC (106/L) 9e1088 240e1222 0.052
Sex (M/F) 20/7 18/9 0.766
Small for date* 12/27 4/27 0.035
Maternal hypertension 15/27 10/27 0.275
1-min Apgar score 0e9 1e8 0.207
5-min Apgar score 2e9 1e10 0.261
Nosocomial infection* 16/27 4/27 0.002
Episode(s) of NI*
1 12 4 0.007
2 4 0
Death 9/27 4/27 0.202
NEC 1/27 1/27 1.000
CLD 9/17 13/23 1.000
PDA 7/27 7/27 1.000
IVH
I 5 3 0.669
II 1 3
III 7 10
Pathogen(s)
Gram-positive 11 2
CONS 5 1
Enterococcus 3 1
MRSA 2
Staphylococcus aureus 1
Gram-negative 9 1
Escherichia coli 1 1
Klebsiella pneumoniae 4
Enterobacter 3
Pseudomonas aeruginosa 1
Candida sp. 4 1
*p < 0.05.
CLD Z chronic lung disease; CONS Z coagulase negative
Staphylococcus aureus; IVH Z intraventricular hemorrhage;
MRSA Z methicillin-resistant Staphylococcus aureus;
NEC Z necrotizing enterocolitis; NI Z nosocomial infection;
PDAZ patent ductus arteriosus; rhG-CSFZ recombinant human
granulocyte-colony-stimulating factor; TNC Z total neutrophil
count.
Figure 2 Log-rank test for the probability of NI between two
groups. The data were censored with fatal cases. The rhG-CSF
(þ) group has significantly higher hazard ratio for having NI.
Figure 3 Changes in total neutrophil count after rhG-CSF
treatment for early neutropenia.
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has been shown to improve the phagocytic function and
oxidative burst activity of the neutrophils, especially in the
presence of sepsis.10 However, despite the efficacy of rhG-
CSF in ameliorating neutropenia,8 this effect has not been
translated into a reduction of NI.12
We have previously demonstrated that irrespective of
the status of maternal blood pressure, EN by itself is not
associated with a higher incidence of NI.14 This led us to
question if empirical rhG-CSF use would be efficacious in
preventing NI in VLBW infants with EN. In the present study
we did not attempt to separate infants according tomaternal blood pressure status during pregnancy for anal-
ysis due to the limited numbers of infants. The finding that
empirical rhG-CSF for EN had increased the likelihood for NI
was unexpected. We cannot account for this finding based
upon neutropenia alone because all infants in rhG-CSF (þ)
group showed an increase of TNC after the first dose of rhG-
CSF. Furthermore, the increase in TNC did not differ
between those who later developed NI versus those who did
not within the subgroup of rhG-CSF (þ) infants. Although
the rhG-CSF (þ) group had a higher proportion of small for
date infants, this factor was not predictive in the multi-
variate logistic regression analysis of a higher risk for NI. It
is possible that other factors associated with EN contrib-
uted to the increased incidence of NI in this group.
Compared to the study conducted by Kuhn et al,12 the age
of rhG-CSF treatment is less in our group (mean 1.3 days vs.
4.3 days) and we included all NI during the hospitalization
instead of 4 weeks after rhG-CSF treatment. We chose neu-
tropenia developed within the first 7 days since we observed
that most VLBW infants with this kind of EN recovered
spontaneously without treatment and it is not associated
with increased risk of NI.14 Another reason for us to choose
the first 7 days to define our EN was the fact that most VLBW
will still have their central lines and/or are endotracheally
intubated, which could lead to higher chance of NI. Both
studies fail to show long-term efficacy of prophylactic rhG-
CSF for neonatal neutropenia in preventing NI.
178 R.-J. Teng et al.There are several weaknesses in our study. First,
because of the nonrandomized nature of this investigation,
we might have missed identification of other factors that
contribute to the risk of NI. Second, our study was limited
to infants with EN. Third, due to limited case numbers, we
cannot analyze the efficacy of rhG-CSF in premature infants
with EN due to early infections. Most infants were clinically
stable so that the TNC after one week of life was not
available in most cases. Fourth, and more importantly,
there were more hypertensive mothers in the rhG-CSF (þ)
group, which might have influenced the increased number
of small for date infants in this group and thus increased the
likelihood of NI.6,7 However, our statistical analysis did not
identify maternal hypertension or small for dates as risk
factors for NI.
Despite these methodological weaknesses, we believe
that it is important for the practicing neonatologist to be
cautious in treating VLBW infants with EN by empirical rhG-
CSF (þ) in the hope of preventing the development of NI.
Our study underscores the importance of the judicious use
of, rather than routine prophylaxis with, rhG-CSF in VLBW
infants with EN. There are several potential adverse effects
of rhG-CSF administration such as injection pain, local
tenderness after injection, bone pain, fever, hemogram
derangement (thrombocytopenia and neutrophilia),29,30
NEC and CLD.31 Most of these adverse effects are very
difficult to identify in VLBW infants by health professionals
and documented relatively subjective. Parenteral admin-
istration potentially increases the possibility of infection
but we did not identify any NI secondary to the intravenous
rhG-CSF infusion. Long-term rhG-CSF use in severe
congenital neutropenia may increase the chance of
leukemia32 but should not be a concern in short-term use in
our study. Our study findings support the need for
a randomized controlled trial designed to establish whether
administration of rhG-CSF to premature infants with neu-
tropenia will reduce the risk of NI or not.Conclusion
Our data suggest that empirical rhG-CSF does not associate
with a decreased rate NI in VLBW infants with EN. However,
we cannot conclude that the use of rhG-CSF is the direct
cause for the increase in NI due to the retrospective non-
randomized nature of our study. A randomized clinical trial
is needed to determine whether rhG-CSF treatment of EN
will reduce the incidence of NI. Our findings do not support
the empirical administration of rhG-CSF for the prevention
of NI in VLBW infants with EN and each institute should
establish a strict guideline about when to prescribe this
cytokine to prevent NI.References
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